Abstract:Background: Many cancers including head and neck squamous cell carcinoma (HNSCC) are characterized by a metabolic rewiring with increased glucose uptake and lactate production, termed as aerobic glycolysis. Targeting aerobic glycolysis presents a promising strategy for cancer therapy. This study investigates the therapeutic potential of glycolysis blockage by targeting phosphofructokinase-2/fructose-2, 6-bisphosphatase 3 (PFKFB3) in HNSCC.Methods: 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK15) was used as a selective antagonist of PFKFB3. Glycolytic flux was determined by measuring glucose uptake, lactate production and ATP yield. PFKFB3 expression was examined using HNSCC tissue arrays. Cell proliferation, apoptosis and motility were analysed. HNSCC xenograft mouse model and metastasis mouse model were established to examine the therapeutic efficacy of PFK15 in vivo.Results: HNSCC showed an increased PFKFB3 expression compared with adjacent mucosal tissues (P < 0.01). Targeting PFKFB3 via PFK15 significantly reduced the glucose uptake, lactate production and ATP generation in HNSCC cell lines. PFK15 suppressed cell proliferation, halted cell cycle progression and induced cell apoptosis. The invadopodia of HNSCC cells was markedly reduced after PFK15 treatment, thereby impairing cell motility and extracellular matrix degradation ability. The in vivo data from the xenograft mice models proved that PFK15 administration suppressed the tumor growth. And the results from the metastatic mice models showed administration of PFK15 alleviated the lung metastasis of HNSCC and extended the life expectancy of mice.Conclusions: The pharmacological inhibition of PFKFB3 via PFK15 suppressed tumor growth and alleviated metastasis in HNSCC, offering a promising strategy for cancer therapy.

PFKFB3 Blockade Inhibits Hepatocellular Carcinoma Growth by Impairing DNA Repair Through AKT

Overexpression of PFKFB3 promotes cell glycolysis and proliferation in renal cell carcinoma

PFKFB3 Regulates Chemoresistance, Metastasis and Stemness via IAP Proteins and the NF-κB Signaling Pathway in Ovarian Cancer

FKBP4 promotes glycolysis and hepatocellular carcinoma progression via p53/HK2 axis

Blockage of Glycolysis by Targeting PFKFB3 Suppresses Tumor Growth and Metastasis in Head and Neck Squamous Cell Carcinoma

Non-canonical Roles of PFKFB3 in Regulation of Cell Cycle Through Binding to CDK4.

KIFC3 regulates progression of hepatocellular carcinoma via EMT and the AKT/mTOR pathway

Acetylation Accumulates PFKFB3 in Cytoplasm to Promote Glycolysis and Protects Cells from Cisplatin-Induced Apoptosis

Over-expression of Fibroblast Growth Factor Receptor 3 in Human Hepatocellular Carcinoma

PFKFB3 is Involved in Breast Cancer Proliferation, Migration, Invasion and Angiogenesis

Glycolytic Regulatory Enzyme PFKFB3 As a Prognostic and Tumor Microenvironment Biomarker in Human Cancers.

Glucose Metabolism Inhibitor PFK-015 Combined with Immune Checkpoint Inhibitor is an Effective Treatment Regimen in Cancer.

KLF9 (kruppel Like Factor 9) Induced PFKFB3 (6-Phosphofructo-2-kinase/fructose-2, 6-Biphosphatase 3) Downregulation Inhibits the Proliferation, Metastasis and Aerobic Glycolysis of Cutaneous Squamous Cell Carcinoma Cells

Identification of PFKFB3 as a key factor in the development of colorectal cancer and immunotherapy resistance

PD173074 Blocks G1/S Transition Via CUL3-mediated Ubiquitin Protease in HepG2 and Hep3B Cells.

PFKFB3 regulates breast cancer tumorigenesis and Fulvestrant sensitivity by affecting ERα stability

Inhibition of proliferation and migration of hepatocellular carcinoma by knockdown of KIF3A via NF-κB signal pathway

CK-3, A Novel Methsulfonyl Pyridine Derivative, Suppresses Hepatocellular Carcinoma Proliferation and Invasion by Blocking the PI3K/AKT/mTOR and MAPK/ERK Pathways

PFKFB3 deprivation attenuates the cisplatin resistance via blocking its autophagic elimination in colorectal cancer cells

PFKFB3 Was Overexpressed in Gastric Cancer Patients and Promoted the Proliferation and Migration of Gastric Cancer Cells.

FCN3 Inhibits the Progression of Hepatocellular Carcinoma by Suppressing SBDS-mediated Blockade of the P53 Pathway